Medindia

X

Cardio Vascular Medical Device Sends Update to Shareholders

Monday, October 26, 2009 General News J E 4
Advertisement
Company Develops Innovative Guidewire That Improves Angioplasty Procedures

HAIFA, Israel, October 26 /PRNewswire-FirstCall/ -- Cardio Vascular Medical Device Corp. (OTC: CVSL), a leading developer of advanced cardiovascular surgery technology, today released a brief shareholders update.

Cardio Vascular Medical Device holds a US patent for an innovative next-generation "steerable guidewire" applicable for all angioplasty (PCTA) procedures. The guidewire has a unique opportunity to become the guidewire of choice for surgeons throughout the world.

The technology hinges on a bendable tip that improves guidewire performance, enables faster procedure completion, and provides cost benefits for patients as well as healthcare providers.

"Cardio Vascular Medical Device has developed a technology that provides several advantages over the current guidewires being employed in angioplasty procedures," stated Eli Gonen, CEO of Cardio Vascular Medical Device Corp. "And with well over 7 million angioplasties performed each year, the global annual potential addressable market in excess of $500 million."

Cardio Vascular Medical Device is working diligently to complete the development of the guidewire, in preparation for full commercial distribution.

Cardio Vascular Medical Device Corp. plans to keep public shareholders informed of all upcoming company developments.

Forward-Looking Statements

This letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of Cardio Vascular Medical Device Corp. and its technologies. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release, as actual results may differ materially from those indicated in the forward-looking statements. Cardio Vascular Medical Device Corp. public filings may be viewed at http://www.sec.gov.

    Contact: Alex Traiman, Media Relations, +1-646-863-9729;
    Asher Zwebner, +972-54-464-6363, asher@fxmng.com



SOURCE Cardio Vascular Medical Device Corp.

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Champions Biotechnology Expands Collaboration to T...
S
Keryx Biopharmaceuticals, Inc. Announces Upcoming ...